Tweet
Vaccine. 2016 Feb 19. pii: S0264-410X(16)00170-5. doi: 10.1016/j.vaccine.2016.02.028. [Epub ahead of print]
Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.
Mullin J1, Ahmed MS1, Sharma R2, Upile N2, Beer H2, Achar P3, Puksuriwong S1, Ferrara F4, Temperton N4, McNamara P5, Lambe T6, Gilbert SC6, Zhang Q7.
Author information
Abstract
Recent efforts have been focused on the development of vaccines that could induce broad immunity against influenza virus, either through T cell responses to conserved internal antigens or B cell response to cross-reactive haemagglutinin (HA). We studied the capacity of Modified Vaccinia Ankara (MVA)-vectored influenza vaccines to induce cross-reactive immunity to influenza virus in human nasopharynx-associated lymphoid tissue (NALT) in vitro. Adenotonsillar cells were isolated and stimulated with MVA vaccines expressing either conserved nucleoprotein (NP) and matrix protein 1 (M1) (MVA-NP-M1) or pandemic H1N1 HA (MVA-pdmH1HA). The MVA vaccine uptake and expression, and T and B cell responses were analyzed. MVA-vectored vaccines were highly efficient infecting NALT and vaccine antigens were highly expressed by B cells. MVA-NP-M1 elicited T cell response with greater numbers of IFNγ-producing CD4+ T cells and tissue-resident memory T cells than controls. MVA-pdmH1HA induced cross-reactive anti-HA antibodies to a number of influenza subtypes, in an age-dependent manner. The cross-reactive antibodies include anti-avian H5N1 and mainly target HA2 domain.
CONCLUSION:
MVA vaccines are efficient in infecting NALT and the vaccine antigen is highly expressed by B cells. MVA vaccines expressing conserved influenza antigens induce cross-reactive T and B cell responses in human NALT in vitro, suggesting the potential as mucosal vaccines for broader immunity against influenza.
Copyright ? 2016. Published by Elsevier Ltd.
KEYWORDS:
Antibody response; Children and adults; Influenza vaccine; MVA-vectored vaccine; Mucosal immunity; Nasopharynx-associated lymphoid tissue (NALT)
PMID: 26902548 [PubMed - as supplied by publisher]
Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.
Mullin J1, Ahmed MS1, Sharma R2, Upile N2, Beer H2, Achar P3, Puksuriwong S1, Ferrara F4, Temperton N4, McNamara P5, Lambe T6, Gilbert SC6, Zhang Q7.
Author information
Abstract
Recent efforts have been focused on the development of vaccines that could induce broad immunity against influenza virus, either through T cell responses to conserved internal antigens or B cell response to cross-reactive haemagglutinin (HA). We studied the capacity of Modified Vaccinia Ankara (MVA)-vectored influenza vaccines to induce cross-reactive immunity to influenza virus in human nasopharynx-associated lymphoid tissue (NALT) in vitro. Adenotonsillar cells were isolated and stimulated with MVA vaccines expressing either conserved nucleoprotein (NP) and matrix protein 1 (M1) (MVA-NP-M1) or pandemic H1N1 HA (MVA-pdmH1HA). The MVA vaccine uptake and expression, and T and B cell responses were analyzed. MVA-vectored vaccines were highly efficient infecting NALT and vaccine antigens were highly expressed by B cells. MVA-NP-M1 elicited T cell response with greater numbers of IFNγ-producing CD4+ T cells and tissue-resident memory T cells than controls. MVA-pdmH1HA induced cross-reactive anti-HA antibodies to a number of influenza subtypes, in an age-dependent manner. The cross-reactive antibodies include anti-avian H5N1 and mainly target HA2 domain.
CONCLUSION:
MVA vaccines are efficient in infecting NALT and the vaccine antigen is highly expressed by B cells. MVA vaccines expressing conserved influenza antigens induce cross-reactive T and B cell responses in human NALT in vitro, suggesting the potential as mucosal vaccines for broader immunity against influenza.
Copyright ? 2016. Published by Elsevier Ltd.
KEYWORDS:
Antibody response; Children and adults; Influenza vaccine; MVA-vectored vaccine; Mucosal immunity; Nasopharynx-associated lymphoid tissue (NALT)
PMID: 26902548 [PubMed - as supplied by publisher]